Alloy Prescription and Intake Process: How It Works, What to Expect, and Whether It's Worth It

What Alloy Is and Who Provides the Medical Care

Alloy Health operates the website, technology, support, and delivery experience. Its current terms state that Alloy itself is not a medical group; telemedicine care is provided by independent U.S.-based practitioners 3. That distinction is more precise than describing every part of the service as care delivered by Alloy employees.

Alloy's current consultation page says patients complete a short assessment, receive an assigned menopause-trained doctor, exchange messages in a secure portal, and receive a personalized plan. If the patient confirms a recommended prescription, Alloy advertises free shipment and unlimited clinician messaging for prescription customers 1.

This is principally an asynchronous pathway. That can be convenient, but a written assessment is not automatically equivalent to a comprehensive in-person evaluation. The value depends on the completeness of the history, the clinician's follow-up questions, and whether the patient's situation can be assessed safely without an examination or new testing.

How the Prescription Process Works

1. Complete the assessment. Expect questions about symptoms, menstrual history, prior treatment, medicines, allergies, reproductive organs and surgeries, and medical and family history.
2. Pay the consultation fee. Alloy advertised a one-time $49 consultation fee when this page was reviewed 1.
3. Message with the assigned clinician. The clinician can ask for clarification or additional records before recommending treatment.
4. Receive a clinical decision. A plan may include prescription treatment, a nonprescription option, additional evaluation, or no prescription. Alloy's terms explicitly say prescription products require a consultation and a provider determination that the product is appropriate 3.
5. Review the exact product and price. Confirm medication name, formulation, dose, quantity, subscription interval, renewal terms, and what is included before paying.
6. Choose fulfillment. Alloy advertises home delivery. Its terms also say a patient may request transfer of an issued prescription to a pharmacy of their choice 3.
7. Plan follow-up. Ask how to report side effects, unexpected bleeding, inadequate relief, a dose change, or a decision to stop treatment.

Alloy advertises a plan in as little as 12 hours 2. That wording describes the fastest marketed turnaround, not a universal completion time. The earlier version of this page incorrectly converted marketing language into a guaranteed 24-to-48-hour prescription timeline.

Current Prices and What the Numbers Mean

The following were the public prices shown by Alloy on July 31, 2026 2 4:

Prices and available products can change. “Starting at” is not the same as the final cost for every dose or formulation. Before ordering, verify the current checkout price, supply length, renewal date, cancellation deadline, shipping terms, and whether the clinician fee is separate.

Alloy's terms describe recurring subscriptions and say cancellation must occur before the applicable deadline. They also say service and consultation fees are nonrefundable and prescription products cannot be returned once dispensed 3. Read the current checkout terms rather than relying on an older review.

What Alloy Currently Offers

Alloy's current product catalog includes systemic estradiol as a patch, pill, gel, or spray; progesterone; vaginal estradiol; and nonhormonal paroxetine, among other products 4. Availability and suitability are separate questions: a clinician should match the product to symptoms, anatomy, risk factors, preferences, and treatment goals.

Systemic therapy treats symptoms throughout the body, such as hot flashes and night sweats. Local low-dose vaginal estrogen is used primarily for genitourinary symptoms. For a person with a uterus who uses systemic estrogen, endometrial protection with an appropriate progestogen is generally important. ACOG explains that estrogen without progestin can increase endometrial-cancer risk in a person with a uterus, while adding progestin reduces that risk 5.

The 2022 Menopause Society position statement concludes that hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause, but emphasizes that risks differ by type, dose, duration, route, timing, and use of a progestogen 6. That supports individualized selection; it does not establish that one platform or formulation is best for everyone.

What the Evidence Supports and What It Does Not

For many symptomatic people younger than 60 or within 10 years of menopause onset who have no contraindications, the 2022 position statement describes a generally favorable benefit-risk balance. Starting systemic therapy later can carry a less favorable balance because absolute cardiovascular, clotting, stroke, and dementia risks rise with age and time since menopause 6.

Route matters, but it should not be oversimplified. A large 2019 observational analysis found oral hormone therapy associated with increased venous-thromboembolism risk while transdermal preparations were not associated with increased risk in that dataset 7. Because this was observational evidence, it does not prove that every patch regimen is risk-free or appropriate.

The PEPI trial found substantially more endometrial hyperplasia with unopposed conjugated estrogen than with placebo; the estrogen-plus-progestogen regimens studied had rates similar to placebo 8. The earlier page cited the wrong PEPI record and overstated what that trial proved about one modern commercial regimen.

FDA approved labeling changes for several menopausal hormone-therapy products in February 2026, including removal of certain risk statements from boxed warnings. This does not erase product-specific risks or replace an individualized discussion; the current label for the exact prescribed product remains controlling 9.

What a Careful Intake Should Clarify

A useful evaluation should distinguish menopause symptoms from problems that need separate investigation. It should cover:

• age, menstrual pattern, and time since the final menstrual period;
• whether the uterus is present;
• unexplained vaginal bleeding;
• personal history of breast or endometrial cancer, blood clots, stroke, heart attack, or liver disease;
• cardiovascular and clotting risk factors;
• migraine history, current medicines, allergies, and pregnancy possibility;
• the symptoms being treated and whether local or systemic therapy fits them; and
• screening, primary-care, and follow-up needs outside the telehealth service.

ACOG lists prior breast or endometrial cancer, stroke, heart attack, blood clots, liver disease, and pregnancy among circumstances in which systemic hormone therapy is usually not recommended 5. A page cannot decide whether an individual exception, specialist pathway, or nonhormonal treatment is appropriate.

Routine hormone-level testing is not required to diagnose typical menopause in every patient. Conversely, “no labs required” should not be interpreted as “testing is never useful.” New bleeding, uncertain diagnosis, cardiovascular concerns, or another medical issue may warrant testing, examination, imaging, or referral based on the history.

Is Alloy Legitimate?

The useful answer is specific:

• The service describes a real clinician consultation and requires a provider to authorize prescription products 1 3.
• The terms identify the dispensing pharmacies and permit prescription transfer 3.
• The catalog includes familiar prescription menopause therapies 4.
• A legitimate prescription pathway does not guarantee that every patient, product, price, or asynchronous interaction is a good fit.

Before paying, verify the assigned clinician's identity and license, the dispensing pharmacy, the exact medication and manufacturer, the full recurring cost, and how urgent or complex problems are escalated.

Is Alloy Worth It?

Alloy may offer strong value when the main barriers are finding a menopause-focused clinician, scheduling, pharmacy coordination, or home delivery. The combination of a low consultation fee, asynchronous messaging, and transparent public pricing can make the process easier to compare.

It may offer weaker value when an existing clinician will prescribe the same medicine through insurance, when a local pharmacy's cash price is lower, or when the patient prefers a live visit. It is also a weaker first stop for urgent symptoms, unexplained bleeding, major diagnostic uncertainty, or a complex cancer, cardiovascular, clotting, or liver history.

Use a like-for-like comparison:

• consultation and follow-up fees;
• medication price for the same drug, dose, and quantity;
• shipping and subscription terms;
• insurance or HSA/FSA treatment;
• access to live visits, examinations, labs, and imaging;
• clinician continuity and response time; and
• prescription-transfer and cancellation options.

The best choice is the route that provides an appropriate clinical evaluation and a sustainable total cost, not simply the fastest advertised plan.